On Monday, Michaels Companies Inc (NASDAQ:MIK)’s shares declined -4.06% to $22.70.
Summer’s hottest book trend — coloring books for adults — will continue through fall and into the holiday season, according to market leader Michaels (MIK), the world’s largest arts and crafts specialty retailer.
Michaels, which has sold the books for more than a decade, has a 15 percent market share of the adult coloring book business, based on BookScan data, and has seen about a one-third jump in sales so far this year over last year. Social media has assisted drive the trend, with more than 400,000 posts on Instagram with #coloringbook.
The Michaels Companies, Inc. owns and operates a chain of arts and crafts specialty retail stores under the Michaels and Aaron Brothers names in North America. The company’s Michaels stores offer about 35,000 stock-keeping units in arts, crafts, framing, floral, home décor and seasonal, scrapbooking, and seasonal merchandise. Its Aaron Brothers stores offer about 7,000 stock-keeping units, counting photo frames, a line of ready-made frames, art prints, framed art, art supplies, and custom framing services.
Thor Industries, Inc. (NYSE:THO)’s shares dropped -1.86% to $50.68.
Thor Industries, Inc. (THO), the sole owner of operating auxiliaries that, combined, represent one of the world’s largest manufacturers of recreational vehicles, declared that its Heartland Recreational Vehicles, LLC partner (“Heartland”) has selected Nampa, Idaho, as the location for its new manufacturing facility to produce the company’s popular Heartland line of travel trailers. Once accomplished, Heartland anticipates to use the manufacturing facility to expand production for West Coast markets. The total estimated investment is about $11-12 million for the 248,000 square-foot facility, which is predictable to employ about 120 new workers and start production in the first quarter of calendar 2016.
Thor Industries, Inc., through its auxiliaries, designs, manufactures, and sells a range of recreational vehicles, and related parts and accessories primarily in the United States and Canada. It operates through two segments, Towable Recreational Vehicles and Motorized Recreational Vehicles .
At the end of Monday’s trade, Lennar Corporation (NYSE:LEN)‘s shares dipped -5.69% to $47.59.
Lennar Corporation (NYSE:LEN), one of the nation’s largest homebuilders, recently stated results for its third quarter ended August 31, 2015. Third quarter net earnings attributable to Lennar in 2015 were $223.3 million, or $0.96 per diluted share, contrast to third quarter net earnings attributable to Lennar in 2014 of $177.8 million, or $0.78 per diluted share.
Mr. Miller continued, “Our core homebuilding business continued to produce strong operating results in the third quarter. Gross and operating margins were 24.1% and 14.1% in the third quarter, respectively. Our average sales price of homes delivered raised 5% year-over-year to $350,000, from $332,000 in the third quarter of 2014. Our new home deliveries raised 16% in the third quarter, while our new home orders raised a solid 10%, contrast to the same period last year. Our sales backlog dollar value raised 22% from the third quarter of last year to about $3.0 billion, keeping us well positioned going forward.
Lennar Corporation, together with its auxiliaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Homebuilding Southeast Florida, Homebuilding Houston, Financial Services, Rialto, and Lennar Multifamily segments.
Amicus Therapeutics, Inc. (NASDAQ:FOLD), ended its Monday’s trading session with -7.18% loss, and closed at $13.19.
Amicus Therapeutics (FOLD), a biotechnology company at the forefront of rare and orphan diseases, recently declared that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the LEERINK Partners 4th Annual Rare Disease Roundtable in New York, NY on Wednesday, September 30, 2015 at 2:45 p.m. ET.
Amicus Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
